[go: up one dir, main page]

MX2022004909A - Una preparación farmaceutica que comprende un derivado de amida e inhibe el crecimiento de celulas cancerígenas y un producto farmaceutico que contiene la preparación. - Google Patents

Una preparación farmaceutica que comprende un derivado de amida e inhibe el crecimiento de celulas cancerígenas y un producto farmaceutico que contiene la preparación.

Info

Publication number
MX2022004909A
MX2022004909A MX2022004909A MX2022004909A MX2022004909A MX 2022004909 A MX2022004909 A MX 2022004909A MX 2022004909 A MX2022004909 A MX 2022004909A MX 2022004909 A MX2022004909 A MX 2022004909A MX 2022004909 A MX2022004909 A MX 2022004909A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
growth
same
cancer cell
pharmaceutical
Prior art date
Application number
MX2022004909A
Other languages
English (en)
Inventor
Taek Kwan Kwon
Ho Taek Im
Yong Il Kim
Young Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200137829A external-priority patent/KR102812658B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2022004909A publication Critical patent/MX2022004909A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una preparación farmacéutica que comprende gránulos que contienen un compuesto de la Fórmula Química 1 o una sal farmacéuticamente aceptable de la misma, y un diluyente. La preparación farmacéutica posee una elevada productividad de la preparación debido a las excelentes propiedades de formación de comprimidos, la friabilidad, y la uniformidad de masa. La preparación farmacéutica presenta una reducida generación de impurezas y una alta estabilidad.
MX2022004909A 2019-10-24 2020-10-23 Una preparación farmaceutica que comprende un derivado de amida e inhibe el crecimiento de celulas cancerígenas y un producto farmaceutico que contiene la preparación. MX2022004909A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190132809 2019-10-24
KR1020200137829A KR102812658B1 (ko) 2019-10-24 2020-10-22 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
PCT/KR2020/014577 WO2021080375A1 (en) 2019-10-24 2020-10-23 A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same

Publications (1)

Publication Number Publication Date
MX2022004909A true MX2022004909A (es) 2022-07-12

Family

ID=75620542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004909A MX2022004909A (es) 2019-10-24 2020-10-23 Una preparación farmaceutica que comprende un derivado de amida e inhibe el crecimiento de celulas cancerígenas y un producto farmaceutico que contiene la preparación.

Country Status (9)

Country Link
US (1) US20220378790A1 (es)
EP (1) EP4048234A4 (es)
JP (1) JP7675071B2 (es)
CN (1) CN114502144A (es)
BR (1) BR112022007744A2 (es)
CA (1) CA3155373A1 (es)
IL (1) IL292455A (es)
MX (1) MX2022004909A (es)
WO (1) WO2021080375A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998505B2 (en) * 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
JP2015078182A (ja) * 2013-09-14 2015-04-23 富士化学工業株式会社 速崩壊性圧縮成型物及びその製法
SG11201700147SA (en) * 2014-07-25 2017-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
HUE061809T2 (hu) * 2014-12-24 2023-08-28 Principia Biopharma Inc Készítmények csípõbél-éhbél szakaszba történõ hatóanyag beadáshoz
CN107789328B (zh) * 2016-09-07 2021-02-26 成都康弘药业集团股份有限公司 一种含有盐酸多奈哌齐的口崩片及其制备方法
JP2018145095A (ja) * 2017-03-01 2018-09-20 沢井製薬株式会社 エルロチニブ塩酸塩含有医薬組成物
WO2018213770A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
CN109692164A (zh) * 2017-10-20 2019-04-30 深圳信立泰药业股份有限公司 化合物a或其盐的药物组合物及其制备方法
KR102622198B1 (ko) * 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법

Also Published As

Publication number Publication date
EP4048234A1 (en) 2022-08-31
JP7675071B2 (ja) 2025-05-12
US20220378790A1 (en) 2022-12-01
EP4048234A4 (en) 2023-11-29
WO2021080375A1 (en) 2021-04-29
AU2020371023A1 (en) 2022-05-19
BR112022007744A2 (pt) 2022-07-19
IL292455A (en) 2022-06-01
CN114502144A (zh) 2022-05-13
CA3155373A1 (en) 2021-04-29
JP2022553744A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
WO2020227549A8 (en) MODULATORS OF THR-β AND METHODS OF USE THEREOF
ZA202206923B (en) New methylquinazolinone derivatives
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
MX2022006470A (es) Tiromimeticos novedosos.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
PH12021552513A1 (en) Pyrrole compounds
MX2022013401A (es) Compuestos de azalactama como inhibidores de hpk1.
NZ754922A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021552953A1 (en) Tricyclic compounds
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
MY201006A (en) Novel Amino Aryl Derivative Useful As Diacylglycerol Acyltransferase 2 Inhibitor And Use Thereof
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2022004909A (es) Una preparación farmaceutica que comprende un derivado de amida e inhibe el crecimiento de celulas cancerígenas y un producto farmaceutico que contiene la preparación.
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
CR20230218A (es) Nuevos derivados de indazol acetileno
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.